相关实验视频

Updated: May 30, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

西维莱斯塔特通过减少NETs形成来防止脏缺血/再损伤

Yanqi Liu¹, Yu Xin¹, Mengyao Yuan¹

¹Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150001, China; Heilongjiang Provincial Key Laboratory of Critical Care Medicine, Harbin, 150001, China; Central Laboratory of the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.

Archives of biochemistry and biophysics

|January 25, 2025

概括

西维莱斯塔治疗可以减少中性粒细胞外细胞陷 (NETs) 和缺血-再输液损伤 (IRI) 中的损伤. 这种疗法通过减少炎症,氧化应激和细胞死亡来改善功能.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
免疫学免疫学免疫学
病理学病理学病理学

背景情况:

缺血-再输液损伤 (IRI) 通常会导致损伤.
中性细胞细胞外陷 (NETs) 在IRI中存在,但它们的作用尚不清楚.
西维莱沙特抑制中性粒细胞弹性酶,这是NET形成中的关键酶.

研究的目的:

研究NETs在脏IRI中的作用.
评估西维莱斯塔特在缓解脏IRI方面的治疗潜力.

主要方法:

建立了早期脏IRI的小鼠模型.
评估了使用免疫光学和西欧斑块的NET参与.
通过组织学染色,ELISA,RT-GFR,PCR和生物化学分析评估功能和病理学.

主要成果:

在IRI后24小时内,NET达到峰值.
西维莱斯塔治疗减少了NET标志物 (MPO,CitH3),管道损伤和炎症性细胞因子 (IL-6,TNF-α).
治疗还降低了氧化应激标志物 (MDA,4HNE),改善了功能标志物 (肌素,BUN,NGAL,KIM-1),减少了亡,增强了GFR.

结论:

西维莱斯塔特有效地改善了脏IRI.
该药物通过降低NETs的调节而起作用,从而减少炎症,氧化应激和亡.
这导致IRI后整体功能得到改善.

关键词:

急性损伤是什么?急性损伤是什么?缺血-再输液损伤缺血-再输液损伤中性粒细胞弹性酶.中性粒细胞外细胞陷西维莱斯塔特.

更多相关视频

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration

Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration

Published on: June 7, 2014

A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure

A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure

Published on: July 14, 2016

相关概念视频

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...